Natera Inc Stock Price, News & Analysis

Natera, Inc. (NASDAQ: NTRA) supports the updated guidelines from the International Society for Heart and Lung Transplantation, which recommends donor-derived cfDNA testing for heart transplant surveillance. The new guidelines advocate monthly rejection monitoring for the first six months post-transplant and again at nine and twelve months. Natera's Prospera™ Heart dd-cfDNA test, launched in late 2021, identifies allograft rejection non-invasively. The test has shown clinical validation in studies, enhancing care for heart transplant patients.

Natera, Inc. (NASDAQ: NTRA) announced a study published in JCO Precision Oncology on its ctDNA test, Signatera™, for predicting recurrence in esophageal and gastric cancers (EGCs). The real-world study involved 295 patients and 943 plasma samples. Key findings showed that pre-operative ctDNA was detectable in 96% of patients, while 23.5% post-surgery showed ctDNA presence, correlating with an 81.2% recurrence rate. Signatera proved to be the strongest prognostic factor compared to other clinicopathological factors. This underscores the test's role in better risk stratification and management of EGCs.

Natera, Inc. (NASDAQ: NTRA) will present new data at the 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas, focusing on its Signatera and Empower tests. The presentations will include findings from the LEADER and I-SPY 2 clinical trials concerning breast cancer recurrence monitoring and hereditary cancer risk management. Notable highlights include two posters on December 8 and 9, showcasing the effectiveness of personalized circulating-tumor DNA testing and cell-free DNA monitoring in breast cancer management. Natera aims to provide insights for improved patient care.

Natera has published a clinical experience study showcasing its Panorama SNP-based noninvasive prenatal test (NIPT) for twin pregnancies, with findings based on 18,984 cases over 27 months. The study demonstrated a positive predictive value (PPV) of 88.7% for trisomy 21 screening, reaching 90.4% when including suggestive findings. Unique to Panorama is its ability to determine zygosity. The study corroborates earlier findings that aneuploidy rates are higher in dizygotic twins. Natera emphasizes its commitment to generating real-world evidence to enhance prenatal care.

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 12:00 p.m. PT (3:00 p.m. ET). CEO Steve Chapman and CFO Mike Brophy will present at the event held at the Lotte New York Palace. A live webcast of the presentation will be accessible on the Natera Investor Relations website and archived for future reference.

Natera, Inc. (Nasdaq: NTRA) announced the pricing of its underwritten public offering of 11,430,000 shares of common stock at $35.00 per share. The offering is expected to close on November 18, 2022, subject to customary conditions. Additionally, Natera has granted underwriters a 30-day option to purchase up to 1,714,500 additional shares. Morgan Stanley, Cowen, and SVB Securities are managing the offering, which is filed under an effective shelf registration statement with the SEC. This issuance aims to support Natera's ongoing operations in cell-free DNA testing for oncology and women's health.

Natera, Inc. (Nasdaq: NTRA), based in Austin, Texas, has announced a proposed follow-on public offering of $350 million in common stock. The offering may include an additional $52.5 million option for underwriters. The offering is subject to market conditions and no assurance can be made regarding its completion or terms. Morgan Stanley, Cowen, and SVB Securities are acting as joint book-running managers, with Baird as co-manager. The offering will be conducted under an effective shelf registration statement filed with the SEC.

Natera, Inc. (NASDAQ: NTRA) reported a strong third quarter for 2022, with total revenues of $210.6 million, up 33.2% from $158.1 million in Q3 2021. Product revenues rose 29.8% to $199.8 million. The company processed approximately 517,500 tests, an increase of 27.1%. Natera raised its revenue guidance for 2022 to $810 million - $830 million. Although net loss reduced from $151.3 million in Q3 2021 to $121.5 million, gross margin declined from 48.5% to 44.7% due to rising labor costs.

Natera, Inc. (NASDAQ: NTRA) has secured a nationwide contract with the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program, effective September 15, 2022. This contract enables the provision of minimal residual disease (MRD) and monitoring services using the Signatera™ test, aimed at detecting cancer recurrence and informing treatment decisions. The VA serves over 450,000 veterans with cancer. Signatera™ is validated across multiple cancer types and is covered by Medicare for specific uses, enhancing its clinical utility and accessibility.